Worth reading
66In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
25
% (year-on-year increase in consolidated revenue)Wording
Conditional
How definitive the wording is.Contents of this document
Presentation materials for financial resultsFirst quarter of the fiscal year ending March 20277 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥3,643 million+25.0%
Operating profit¥784 million+24.6%
Ordinary income¥778 million+20.6%
Net income¥623 million+61.0%
Operating profit margin21.5 %
Selling, general and administrative expenses¥1,314 million
Results for the three months of the current quarter
Net Sales
¥3,643 million
Gross profit
¥2,099 million
Operating profit
¥784 million
Ordinary income
¥778 million
Profit attributable to owners of parent for the quarter
¥623 million
EBITDA
¥1,194 million
Full-year earnings forecast
Net Sales
¥14,400 million
Operating profit
¥3,100 million
Ordinary income
¥3,100 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales25%
Operating profit25%
Ordinary income25%
What the company explained in this material
Key points of the Q&AKey questions raised by investors at the briefing and the company's answers
The Company responded to questions concerning whether there were issues with surveys and point awards related to a Ministry of Health, Labour and Welfare administrative notice, the treatment of ongoing record-keeping and check-in points, the continuation of its prescription reservation service, and the impact on results. The Company explained that the related surveys and point awards had ended, the prescription reservation service was expected to continue, and there had been no significant changes to the number of prescriptions received online, the number of pharmacy contracts or the cancellation rate as of the current date. It therefore considered the impact on results to be limited.New initiatives
- Change the name of the Media business to the Healthcare Automation business and the Preventive Healthcare business to the Wellness Platform business
- Promote AI-enabled healthcare operations automation and the Wellness Platform
- Expand the share repurchase authorization to 400,000 shares and ¥800 million
Key KPIsA metric the company considers important as a management benchmark.
- Number of facilities24,694 EngagementsYear on year against the same period last year+1,605 facilities
- Reservations2,012 thousand casesYear on year against the same period last year+400 thousand reservations
- Medication handbook downloads7,667 thousand cases
- Cumulative EPARK Medication Handbook downloads700 10,000 downloads
Segment results
Healthcare Automation business
Net Sales
¥1,620 million+37.3%
Gross profit from recurring revenue
¥620 million+57.3%
Minna no Okusuribako business (medication procurement platform)
Net Sales
¥940 million+7.8%
Gross profit from recurring revenue
¥350 million-8.0%
Core Systems business
Net Sales
¥1,030 million+25.9%
Gross profit from recurring revenue
¥180 million+31.2%
Market Size / Share
Number of prescriptions900 million prescriptions
Target market for the Company's online prescription reception service450 million prescriptions (SAM)
Company shareNot disclosed
Number of pharmacy storesApproximately 63,000 locations
Number of self-service market locationsApproximately 16,800 self-service locations
Number of employees
756 people
Acquisition of treasury shares
Buyback limit
800,000,000
Number of Shares400,000
Share unitShares (maximum)
Amount unitYen (upper limit)
Period8 June 2026 to 7 December 2026
Actual purchases
524,611,400
Number of Shares216,400
Share unitShares
Amount unit¥
Period8 June 2026 to 31 July 2026
| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | First quarter of the fiscal year ending March 2027 |
| Net Sales | ¥3,643 million (YoY +25.0%) |
| Operating profit | ¥784 million (YoY +24.6%) |
| Ordinary income | ¥778 million (YoY +20.6%) |
| Net income | ¥623 million (YoY +61.0%) |
| Operating profit margin | 21.5 % |
| Selling, general and administrative expenses | ¥1,314 million |
| Results for the three months of the current quarter | Net Sales ¥3,643 million / Gross profit ¥2,099 million / Operating profit ¥784 million / Ordinary income ¥778 million / Profit attributable to owners of parent for the quarter ¥623 million / EBITDA ¥1,194 million |
| Full-year earnings forecast | Net Sales ¥14,400 million / Operating profit ¥3,100 million / Ordinary income ¥3,100 million |
| Progress against full-year forecast | Net Sales 25% / Operating profit 25% / Ordinary income 25% |
| Segment results | Healthcare Automation business Net Sales ¥1,620 million (YoY +37.3%) / Gross profit from recurring revenue ¥620 million (YoY +57.3%) / Minna no Okusuribako business (medication procurement platform) Net Sales ¥940 million (YoY +7.8%) / Gross profit from recurring revenue ¥350 million (YoY -8.0%) / Core Systems business Net Sales ¥1,030 million (YoY +25.9%) / Gross profit from recurring revenue ¥180 million (YoY +31.2%) / Wellness Platform business Not disclosed |
| Key KPIs | Number of facilities 24,694 Engagements, Reservations 2,012 thousand cases, Medication handbook downloads 7,667 thousand cases, Cumulative EPARK Medication Handbook downloads 700 10,000 downloads |
| Number of employees | 756 people |
| Acquisition of treasury shares | Buyback limit Number of Shares 400,000 / Share unit Shares (maximum) / Amount 800,000,000 / Amount unit Yen (upper limit) / Period 8 June 2026 to 7 December 2026 / Actual purchases Number of Shares 216,400 / Share unit Shares / Amount 524,611,400 / Amount unit ¥ / Period 8 June 2026 to 31 July 2026 |
| Market Size / Share | Number of prescriptions 900 million prescriptions / Target market for the Company's online prescription reception service 450 million prescriptions (SAM) / Company share Not disclosed / Number of pharmacy stores Approximately 63,000 locations / Number of self-service market locations Approximately 16,800 self-service locations |
| Key points of the Q&A | The Company responded to questions concerning whether there were issues with surveys and point awards related to a Ministry of Health, Labour and Welfare administrative notice, the treatment of ongoing record-keeping and check-in points, the continuation of its prescription reservation service, and the impact on results. The Company explained that the related surveys and point awards had ended, the prescription reservation service was expected to continue, and there had been no significant changes to the number of prescriptions received online, the number of pharmacy contracts or the cancellation rate as of the current date. It therefore considered the impact on results to be limited. |
| New initiatives | Change the name of the Media business to the Healthcare Automation business and the Preventive Healthcare business to the Wellness Platform business, Promote AI-enabled healthcare operations automation and the Wellness Platform, Expand the share repurchase authorization to 400,000 shares and ¥800 million |
Items this document does not state (13)
Gross Profit MarginSelf-assessment against the planBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioCapital expendituresOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company cited the consolidation benefits of M&A, temporary demand arising from legislative changes, and the accumulation of revenue and stock gross profit in the Healthcare Automation business and Core Systems business as reasons for its consolidated results. The decline in stock gross profit in the Minna no Okusuribako business was attributed to a reversal of the prior-year effect, as part of the previous year's revenue shifted into the current quarter due to temporary operational delays associated with a warehouse relocation.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.